Effects of sigma ligands on the cloned μ-, δ- and κ-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes

British Journal of Pharmacology

Volumn 119, Issue 1, 1996, Pages 73-80

  Kobayashi, Toru ^a,b   Ikeda, Kazutaka ^c   Ichikawa, Tomio ^a   Togashi, Shunji ^b   Kumanishi, Toshiro ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

(+) 3 (3 hydroxyphenyl) N (1 propyl)piperidine ((+) 3PPP); (+) cyclazocine; (+) N allylnormetazocine ((+) SKF10047); 1,3 di (2 tolyl)guanidine (DTG); Carbetapentane; G protein activated K+ (GIRK) channel; Haloperidol; Opioid receptor; Xenopus oocytes; ligand

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; BARIUM ION; CYCLAZOCINE; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; KAPPA OPIATE RECEPTOR; LIGAND; MESSENGER RNA; MU OPIATE RECEPTOR; N ALLYLNORMETAZOCINE; NALOXONE; OPIATE AGONIST; OPIATE ANTAGONIST; PENTOXYVERINE; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL; POTASSIUM ION; SIGMA OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MOLECULAR CLONING; NONHUMAN; OOCYTE; POTASSIUM CURRENT; PRIORITY JOURNAL; RECEPTOR BINDING; XENOPUS;

EID: 0029792049     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15679.x     Document Type: Article

References (79)

1. BEART, P.M., O'SHEA, R.D. & MANALLACK, D.T. (1989). Regulation of σ-receptors: high- and low-affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-di(2-tolyl)guanidine. J. Neurochem., 53, 779-788.
2. BOBKER, D.H., SHEN, K.-Z., SURPRENANT, A. & WILLIAMS, J.T. (1989). DTG and (+)-3-PPP inhibit a ligand-activated hyperpolarization in mammalian neurons. J. Pharmacol. Exp. Ther., 251, 840-845.
3. BRENT, P.J. & PANG, G.T. (1995) σ binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur. J. Pharmacol., 278, 151-160.
4. CAMPBELL, B.G., KEANA, J.F.W. & WEBER, E. (1991). σ receptor ligand N,N′-di-(ortho-tolyl)guanidine inhibits release of acetylcholine in the guinea pig ileum. Eur. J. Pharmacol., 205, 219-223.
5. CAMPBELL, B.G., SCHERZ, M.W., KEANA, J.F.W. & WEBER, E. (1989). Sigma receptors regulate contractions of the guinea pig ileum longitudinal muscle/myenteric plexus preparation elicited by both electrical stimulation and exogenous serotonin. J. Neurosci., 9, 3380-3391.
6. CANDURA, S.M., COCCINI, T., MANZO, L. & COSTA, L.G. (1990). Interaction of σ-compounds with receptor-stimulated phosphoinositide metabolism in the rat brain. J. Neurochem., 55, 1741-1748.
7. + channel. J. Biol. Chem., 269, 7839-7842.
8. CHIEN, C.C. & PASTERNAK, G.W. (1994). Selective antagonism of opioid analgesia by a sigma system. J. Pharmacol. Exp. Ther., 271, 1583-1590.
9. CLAY, G.A. & BROUGHAM, L.R. (1975). Haloperidol binding to an opiate receptor site. Biochem. Pharmacol., 24, 1363-1367.
10. COCCINI, T., COSTA, L.G., MANZO, L., CANDURA, S.M., IAPADRE, N., BALESTRA, B. & TONINI, M. (1991). Two subtypes of enteric non-opioid a receptors in guinea-pig cholinergic motor neurons. Eur. J. Pharmacol., 198, 105-108.
11. DEBONNEL, G. (1993). Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J. Psychiatr. Neurosci., 18, 157-172.
12. DEHAVEN-HUDKINS, D.L., HILDEBRAND, L.M., FLEISSNER, L.C. & WARD, S.J. (1991). Lack of correlation between a binding potency and inhibition of contractions in the mouse vas deferens preparation. Eur. J. Pharmacol., 203, 329-335.
13. DEN BOER, J.A., RAVELLI, D.P., HUISMAN, J., OHRVIK, J., VERHOEVEN, W.M.A. & WESTENBERG, H.G.M. (1990). Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology, 102, 76-84.
14. DI CHIARA, G. & IMPERATO, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A., 85, 5274-5278.
15. 2 binding sites in rat heart membrane preparations. Eur. J. Pharmacol., 209, 245-248.
16. BARLEY, B., BURKE, M., LEONARD, B.E., GOURET, C.-J. & JUNIEN, J.-L. (1991). Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor. Brain Res., 546, 282-286.
17. GONZALEZ-ALVEAR, G.M. & WERLING, L.L. (1995). Sigma receptor regulation of norepinephrine release from rat hippocampal slices. Brain Res., 673, 61-69.
18. HARADA, Y., HARA, H. & SUKAMOTO, T. (1994). Binding properties of KB-5492, a novel anti-ulcer agent, at a receptors in porcine gastric fundic mucosa. Eur. J. Pharmacol., 261, 91-96.
19. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. Mol. Pharmacol., 268, 9-18.
20. HENRY, D.J., GRANDY, D.K., LESTER, H.A., DAVIDSON, N. & CHAVKIN, C. (1995). κ-Opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. Mol. Pharmacol., 47, 551-557.
21. 1 muscarinic antagonists interact with σ recognition sites. Life Sci., 49, 1229-1235.
22. + (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ann. NY. Acad. Sci., (in press).
23. + channel. Biochem. Biophys. Res. Commun., 208, 302-308.
24. ITZHAK, Y. (1989). Multiple affinity binding states of the σ receptor: effect of GTP-binding protein-modifying agents. Mol. Pharmacol., 36, 512-517.
25. IYENGAR, S., MICK, S., DILWORTH, V., MICHEL, J., RAO, T.S., FARAH, J.M. & WOOD, P.L. (1990). Sigma receptors modulate the hypothalamic-pituitary-adrenal (HPA) axis centrally: evidence for a functional interaction with NMDA receptors, in vivo. Neuropharmacology, 29, 299-303.
26. JANSEN, K.L.R., FAULL, R.L.M., DRAGUNOW, M. & LESLIE, R.A. (1991). Autoradiographic distribution of sigma receptors in human neocortex, hippocampus, basal ganglia, cerebellum, pineal and pituitary glands. Brain Res., 559, 172-177.
27. 3H]acetylcholine release from rat hippocampal slices. Eur. J. Pharmacol., 200, 343-345.
28. KEATS, A.S. & TELFORD, J. (1964). Narcotic antagonists as analgesics. Clinical aspects. In Molecular Modification in Drug Design. Advances in Chemistry Series, 45. ed. Gould, R.F. pp. 170-176. Washington, DC: American Chemical Society.
29. KENNEDY, C. & HENDERSON, G. (1989). An examination of the putative σ-receptor in the mouse isolated vas deferens. Br. J. Pharmacol., 98, 429-436.
30. KEST, B., MOGIL, J.S., STERNBERG, W.F., PECHNICK, R.N. & LIEBESKIND, J.C. (1995). Antinociception following 1,3-di-o-tolylguanidine, a selective a receptor ligand. Pharmacol. Biochem. Behav., 50, 587-592.
31. KNAPP, R.J., MALATYNSKA, E., COLLINS, N., FANG, L., WANG, J.Y., HRUBY, V.J., ROESKE, W.R. & YAMAMURA, H.I. (1995). Molecular biology and pharmacology of cloned opioid receptors. FASEB J., 9, 516-525.
32. + channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem. Biophys. Res. Commun., 208, 1166-1173.
33. + channels are activated by Gβγ subunits and function as heteromultimers. Proc. Natl. Acad. Sci. U.S.A., 92, 6542-6546.
34. KORPI, E.R., KLEINMAN, J.E., COSTAKOS, D.T., LINNOILA, M. & WYATT, R.J. (1984). Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res., 11, 259-269.
35. KOVOOR, A., HENRY, D.J. & CHAVKIN, C. (1995). Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1). J. Biol. Chem., 270, 589-595.
36. +-channel proteins. Nature, 374, 135-141.
37. 3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc. Natl. Acad. Sci. U.S.A., 81, 4983-4987.
38. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharmacol. Exp. Ther., 238, 739-748.
39. LESLIE, F.M. (1987). Methods used for the study of opioid receptors. Pharmacol. Rev., 39, 197-249.
40. LEWANDER, T., WESTERBERGH, S.-E. & MORRISON, D. (1990). Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr. Scand., 82 (suppl. 358), 92-98.
41. LIU, Y., WHITLOCK, B.B., PULTZ, J.A. & WOLFE, S.A. JR. (1995). Sigma-1 receptors modulate functional activity of rat splenocytes. J. Neuroimmunol., 59, 143-154.
42. LODGE, D. & JOHNSON, K.M. (1990). Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Sci., 11, 81-86.
43. + channel by a G protein-linked mechanism: coexpression in Xenopus oocytes. Mol. Pharmacol., 47, 1035-1040.
44. MANSOUR, A., FOX, C.A., AKIL, H. & WATSON, S.J. (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci., 18, 22-29.
45. MARTIN, W.R., EADES, C.G., THOMPSON, J.A., HUPPLER, R.E. & GILBERT, P.E. (1976). The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther., 197, 517-532.
46. MATSUNO, K., MATSUNAGA, K., SENDA, T. & MITA, S. (1993). Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J. Pharmacol. Exp. Ther., 265, 851-859.
47. MILLAN, M.J. (1990). κ-Opioid receptors and analgesia. Trends Pharmacol. Sci., 11, 70-76.
48. MINAMI, M. & SATOH, M. (1995). Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res., 23, 121-145.
49. 3 dorsal hippocampus by sigma ligands. J. Pharmacol. Exp. Ther., 261, 123-130.
50. MORIO, Y., TANIMOTO, H., YAKUSHIJI, T. & MORIMOTO, Y. (1994). Characterization of the currents induced by sigma ligands in NCB20 neuroblastoma cells. Brain Res., 637, 190-196.
51. + currents in oocytes co-expressing GIRK1, GIRK2 and CIR cDNAs. J. Physiol., 487, 188P.
52. NORTH, R.A., WILLIAMS, J.T., SURPRENANT, A. & CHRISTIE, M.J. (1987). μ and δ receptors belong to a family of receptors that are coupled to potassium channels. Proc. Natl. Acad. Sci. U.S.A., 84, 5487-5491.
53. ÖHMAN, R., LARSSON, M., NILSSON, I.M., ENGEL, J. & CARLSSON, A. (1977). Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Arch. Pharmacol., 299, 105-114.
54. O'NEILL, M., CALDWELL, M., EARLEY, B., CANNEY, M., O'HALLORAN, A., KELLY, J., LEONARD, B.E. & JUNIEN, J.-L. (1995). The σ receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia. Eur. J. Pharmacol., 283, 217-225.
55. PASCAUD, X., DEFAUX, J.P., ROZE, C. & JUNIEN, J.L. (1990). Effect of selective sigma ligands on duodenal alkaline secretion in the rat. J. Pharmacol. Exp. Ther., 255, 1354-1359.
56. 2-like binding site. Neurosci. Lett., 180, 159-162.
57. PFEIFFER, A., BRANTL, V., HERZ, A. & EMRICH, H.M. (1986). Psychotomimesis mediated by κ opiate receptors. Science, 233, 774-776.
58. QUIRION, R., BOWEN, WD, ITZHAK, Y., JUNIEN, J.L., MUSACCHIO, J.M., ROTHMAN, R.B., SU, T.-P., TAM, S.W. & TAYLOR, D.P. (1992). A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci., 13, 85-86.
59. ROMAN, F., PASCAUD, X., VAUCHE, D. & JUNIEN, J.-L. (1988). Evidence for a non-opioid sigma binding site in the guinea-pig myenteric plexus. Life Sci., 42, 2217-2222.
60. SAKIMURA, K., MORITA, T., KUSHIYA, E. & MISHINA, M. (1992). Primary structure and expression of the γ2 subunit of the glutamate receptor channel selective for kainate. Neuron, 8, 267-274.
61. SEEMAN, P. & VAN TOL, H.H.M. (1994). Dopamine receptor pharmacology. Trends Pharmacol. Sci., 15, 264-270.
62. SPANAGEL, R., HERZ, A. & SHIPPENBERG, T.S. (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem., 55, 1734-1740.
63. STEINFELS, G.F. & TAM, S.W. (1989). Selective σ receptor agonist and antagonist affect dopamine neuronal activity. Eur. J. Pharmacol., 163, 167-170.
64. TAM, S.W. (1983). Naloxone-inaccessible σ receptor in rat central nervous system. Proc. Natl. Acad. Sci. U.S.A., 80, 6703-6707.
65. 3H]-ethylketocyclazocine, μ, κ, δ and phencyclidine binding sites in guinea pig brain membranes. Eur. J. Pharmacol., 109, 33-41.
66. 3H]haloperidol binding in guinea pig brain membranes. Proc. Natl. Acad. Sci. U.S.A., 81, 5618-5621.
67. TORTELLA, F.C. & MUSACCHIO, J.M. (1986). Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res., 383, 314-318.
68. TORTELLA, F.C., PELLICANO, M. & BOWERY, N.G. (1989). Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol. Sci., 10, 501-507.
69. TORTELLA, F.C., ROBLES, L. & HOLADAY, J.W. (1986). U50448, a highly selective kappa opioid: anticonvulsant profile in rats. J. Pharmacol. Exp. Ther., 237, 49-53.
70. 3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparitive study. Brain Res., 581, 33-38.
71. 2 receptors in motor function. Eur. J. Pharmacol., 231, 61-68.
72. WALKER, J.M., BOWEN, W.D., WALKER, F.O., MATSUMOTO, R.R., DECOSTA, B. & RICE, K.C. (1990). Sigma receptors: biology and function. Pharmacol, Rev., 42, 355-402.
73. WALKER, J.M., MATSUMOTO, R.R., BOWEN, W.D., GANS, D.L., JONES, K.D. & WALKER, F.O. (1988). Evidence for a role of haloperidol-sensitive σ-'opiate' receptors in the motor effects of antipsychotic drugs. Neurology, 38, 961-965.
74. 3H]tolyl)guanidine: a selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U.S.A., 83, 8784-8788.
75. WOLFE, S.A. JR & DE SOUZA, E.B. (1994). Role of sigma binding sites in the modulation of endocrine and immune functions. In Sigma Receptors ed. Itzhak, Y. pp. 287-317. London: Academic Press.
76. WU, X.-Z., BELL, J.A., SPIVAK, C.E., LONDON, E.D. & SU, T.-P. (1991). Electrophysiological and binding studies on intact NCB-20 cells suggest presence of a low affinity sigma receptor. J. Pharmacol. Exp. Ther., 257, 351-359.
77. WURZBURGER, R.J., MILLER, R.L., MARCUM, E.A., COLBURN, W.A. & SPECTOR, S. (1981). A new radioimmunoassay for haloperidol: direct measurement of serum and striatal concentrations. J. Pharmacol. Exp. Ther., 217, 757-763.
78. YAMAKURA, T., MORI, H., MASAKI, H., SHIMOJI, K. & MISHINA, M. (1993). Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. NeuroReport, 4, 687-690.
79. 3H]cyclazocine binding to multiple opiate receptor sites. Mol. Pharmacol., 20, 246-254.